Assyro AI

FDA Orange Book · active-ingredient family

Finasteride

Finasteride is approved as 2 brand and 22 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:PROPECIA · NDA 020788

2

Brand (NDA)

22

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
PROPECIARLDORGANONNDA 020788ABDec 19, 1997
PROSCARRLDORGANONNDA 020180ABJun 19, 1992

Generic (ANDA) products (22)

ProductApplicantApplicationTEApproved
FINASTERIDEALKEM LABS LTDANDA 207750ABJan 06, 2017
FINASTERIDEALKEM LABS LTDANDA 204304ABJan 05, 2017
FINASTERIDECIPLAANDA 077335Nov 20, 2014
FINASTERIDEACCORD HLTHCAREANDA 091643ABNov 05, 2013
FINASTERIDEACTAVIS TOTOWAANDA 078371Nov 05, 2013
FINASTERIDEAUROBINDO PHARMA LTDANDA 203687ABNov 05, 2013
FINASTERIDENATCO PHARMAANDA 078161Nov 05, 2013
FINASTERIDETEVAANDA 076905Nov 05, 2013
FINASTERIDEHETERO LABS LTD IIIANDA 090060ABJul 01, 2013
FINASTERIDESUN PHARMANDA 090508ABJul 01, 2013
FINASTERIDESUN PHARMANDA 090507ABAug 16, 2011
FINASTERIDEHETERO LABS LTD IIIANDA 090061ABJun 07, 2010
FINASTERIDEACCORD HLTHCAREANDA 090121ABFeb 23, 2010
FINASTERIDEZYDUS PHARMS USA INCANDA 078900ABDec 28, 2009
FINASTERIDEAUROBINDO PHARMAANDA 078341ABOct 30, 2007
FINASTERIDEACTAVIS TOTOWA TEVAANDA 077914Mar 28, 2007
FINASTERIDEDR REDDYS LABS LTDANDA 076437ABFeb 28, 2007
FINASTERIDEGEDEON RICHTER USAANDA 077251Dec 22, 2006
FINASTERIDEMYLANANDA 077578Dec 18, 2006
FINASTERIDETEVAANDA 076511ABDec 15, 2006
FINASTERIDEDR REDDYS LABS INCANDA 076436ABJul 28, 2006
FINASTERIDEIVAX SUB TEVA PHARMSANDA 076340Jun 19, 2006

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Finasteride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.